Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H857

UPID:
NT5D2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H857; C9JTZ6; E9PAL9; O95888; Q96C80; Q9H9Z8

BACKGROUND:
5'-nucleotidase domain-containing protein 2 is integral to the regulation of nucleotide pools within the cell, affecting DNA and RNA synthesis. The detailed mechanisms through which it operates and its broader implications for cellular health are areas of ongoing research.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of 5'-nucleotidase domain-containing protein 2 holds promise for uncovering new therapeutic avenues. Its key role in nucleotide metabolism positions it as a potential target in diseases where nucleotide balance is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.